Skip to main content

Table 2 OCS dose reduction from benralizumab treatment initiation to 96 weeks of treatment

From: Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

Variable

Number (%) of patients with OCS reduction at 48 weeks (N = 34)

Number (%) of patients with OCS reduction at 96 weeks (N = 30)

OCS interruption

18 (52.9)

18 (60.0)

Any OCS reduction (including interruption)

21 (61.8)

20 (66.7)

 ≥ 90% OCS dose reduction

18 (52.9)

18 (60.0)

 ≥ 75% OCS dose reduction

18 (52.9)

18 (60.0)

 ≥ 25% OCS dose reduction

20 (58.8)

19 (63.3)

No OCS reduction

13 (38.2)

10 (33.3)

  1. OCS dosage is expressed as daily mg (prednisone equivalent). Evaluable patients for secondary analyses at 48 and 96 weeks with OCS dose available were considered (N = 34 and N = 30, respectively). Data are expressed as N (%)